title: ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins.
abstract: Small-molecule inhibitors targeted MAPK have been wildly used for some cancer therapeutics as a biologically viable model, but no one has been used for cervical caner. ERK1/2, one of MAPK kinases, is expressed high in cervical cancer tissue. The aim of the present study was to evaluate the effects of ERK1/2 inhibitor U0126 on proliferation and apoptosis of cervical cancer cells and appraise the correlated mechanism of the effects. In this study, the cell proliferation of Hela and C33A cervical cancer cells was tested by Cell Counting Kit-8 (CCK8) assay and cell counting after treated with ERK1/2 inhibitor U0126. The cell cycle and apoptosis were evaluated by flow cytometry (FCM). The protein levels of ERK1/2 and c-Fos and c-Jun were detected by Western blot. The results indicated that after down-regulating ERK1/2 proteins with the inhibitor U0126, Hela and C33A cells proliferation was inhibited, cell apoptosis was promoted, the proportions of G0/G1 stage in cell cycle increased, and G2/M stages decreased. After down-regulating ERK1/2 proteins of Hela and C33A cells, the expression levels of p-c-Fos protein decreased, while p-c-Jun protein increased. The results of this study indicated that ERK1/2 may promote the development of cervical cancer cells, suggesting ERK1/2 inhibitor may be used as an effective target for cervical cancer therapies working for. It might inhibit cervical cancer cells growth via regulating the transcription factors expression of c-Fos and c-Jun.
authors: Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan, 030001, China, bailixia111@163.com.
authors: Lixia
authors: L
authors: Bai
authors: Rui
authors: R
authors: Mao
authors: Jintao
authors: J
authors: Wang
authors: Ling
authors: L
authors: Ding
authors: Shiwen
authors: S
authors: Jiang
authors: Chenfei
authors: C
authors: Gao
authors: Huijie
authors: H
authors: Kang
authors: Xiao
authors: X
authors: Chen
authors: Xuesong
authors: X
authors: Sun
authors: Juan
authors: J
authors: Xu
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002070:Butadienes / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009570:Nitriles / Q000494:pharmacology; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D016755:Proto-Oncogene Proteins c-jun / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*
chemical_list: D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; C113580:U 0126; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references: Asian Pac J Cancer Prev. 2013;14 (12 ):7595-600
references: 24460339
references: Mol Cancer Ther. 2014 Sep;13(9):2141-8
references: 25139999
references: Growth Factors. 2006 Mar;24(1):21-44
references: 16393692
references: Front Oncol. 2014 May 16;4:108
references: 24904824
references: J Clin Oncol. 2004 Nov 15;22(22):4456-62
references: 15483017
references: Arch Pharm Res. 2012 Aug;35(8):1317-33
references: 22941475
references: Rev Prat. 2014 Jun;64(6):774-9
references: 25090759
references: Nat Cell Biol. 2002 May;4(5):E131-6
references: 11988758
references: Pharmacol Res. 2012 Aug;66(2):105-43
references: 22569528
references: Clin Cancer Res. 2010 Mar 15;16(6):1924-37
references: 20215549
references: Prostate. 2014 Jul;74(10):1023-33
references: 24811146
references: Anticancer Drugs. 2002 Sep;13(8):859-68
references: 12394272
references: Eur J Clin Invest. 2013 Nov;43(11):1156-62
references: 23992401
references: J Clin Oncol. 2005 Aug 10;23 (23 ):5281-93
references: 16009947
references: Clin Cancer Res. 2007 Mar 1;13(5):1576-83
references: 17332304
references: Mol Nutr Food Res. 2011 Oct;55(10 ):1572-81
references: 21595016
references: Expert Opin Ther Targets. 2012 Jan;16(1):103-19
references: 22239440
references: Onco Targets Ther. 2014 Jun 12;7:1001-14
references: 24959087
references: Int J Oncol. 2014 Jan;44(1):285-94
references: 24189697
references: Cancer Res. 2014 Jan 15;74(2):412-9
references: 24408923
references: J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
references: 15564374
references: Mol Cancer. 2014 Aug 29;13:201
references: 25174975
references: Gynecol Oncol. 2014 Apr;133(1):128-37
references: 24434059
references: Asian Pac J Cancer Prev. 2014;15(15):6349-52
references: 25124623
references: Oncogene. 2008 Apr 24;27(19):2772-9
references: 18026136
references: Int J Cancer. 2005 Mar 1;113(6):951-60
references: 15514944
references: Exp Cell Res. 2011 Aug 1;317(13):1935-46
references: 21641901